UroGen Pharma (URGN) Misses Q1 EPS by 13c
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($0.92), $0.13 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $20.25 million versus the consensus estimate of $22.5 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jernigan Capital (JCAP) Tops Q2 EPS by 5c
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- HSBC Upgrades Sembcorp Industries (SCI:SP) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
